The Peptide Universe: Natural, Synthetic, and Semi-Synthetic

A Field Defined by Diversity

The peptide universe is far larger and more chemically diverse than any single entry point into the field suggests. A graduate student trained in solid-phase synthesis encounters peptides as designed molecules built from defined building blocks under controlled conditions. A natural products chemist encounters them as complex secondary metabolites with architectures that chemical synthesis has only recently learned to replicate. A biochemist encounters them as signaling molecules, hormones, and antimicrobial agents embedded in elaborate biological contexts. All of these perspectives are correct, and each illuminates a different corner of the same field.

Organizing this diversity into a coherent framework requires distinguishing how peptides are made, their biosynthetic or synthetic origin, from what they do, which is the subject of later chapters. This article addresses origin.

Ribosomally Synthesized Peptides

The ribosome is the most ancient and universal peptide synthesizer. Ribosomally synthesized peptides are encoded in genomic DNA, transcribed into mRNA, and translated by the ribosomal machinery using the twenty canonical amino acids specified by the genetic code. Peptide hormones, including insulin, glucagon, oxytocin, and vasopressin, are the most familiar examples in a human biomedical context. Antimicrobial peptides such as the defensins are produced ribosomally in virtually all kingdoms of life.

Ribosomally synthesized peptides share a fundamental constraint: their primary sequence is limited to the twenty canonical amino acids, plus whatever modifications are introduced after translation. They are also subject to the directional logic of the ribosome, synthesized N-to-C terminus without exception. Within these constraints, evolution has produced an enormous range of structures and functions, and the study of ribosomally synthesized peptides remains one of the most active areas of biological research.

RiPPs: When the Ribosome Is Just the Starting Point

A large and rapidly expanding class of natural peptides begins with ribosomal synthesis but is subsequently transformed by dedicated post-translational modification enzymes into molecules of extraordinary structural complexity. These ribosomally synthesized and post-translationally modified peptides, universally abbreviated RiPPs, include the lanthipeptides, thiopeptides, cyanobactins, lasso peptides, and many other structural families.^[7]

The biosynthetic logic of RiPPs is distinctive. A precursor peptide encoded in the genome contains a leader sequence recognized by the modification enzymes and a core peptide that becomes the final natural product. The enzymes install macrocyclic bridges, heterocyclic rings, unusual amino acids, and other structural features that would be difficult or impossible to introduce by standard solid-phase synthesis. The result is a class of molecules that combines the sequence programmability of ribosomal synthesis with the chemical complexity previously associated only with non-ribosomal pathways. Chapter 29 covers RiPPs in detail.

Non-Ribosomal Peptides

Non-ribosomal peptides are assembled by large multimodular enzyme complexes called non-ribosomal peptide synthetases, universally abbreviated NRPS. These remarkable molecular machines operate entirely independently of the ribosome, using a thiotemplate mechanism in which each module activates, tethers, and condenses a specific building block.^[8] Because NRPS modules can accept a far wider range of substrates than the ribosome, non-ribosomal peptides routinely incorporate D-amino acids, N-methylated residues, beta-amino acids, hydroxy acids, fatty acids, and other non-canonical building blocks.^[9]

The consequences for structural diversity are profound. Among non-ribosomal peptides are three of the most consequential antibiotics in clinical use: vancomycin, cyclosporine, and gramicidin S. So is daptomycin, a lipopeptide antibiotic that represents one of the last lines of defense against certain resistant Gram-positive infections. The structural features that make these molecules effective, their cyclic architectures, unusual amino acids, and lipid appendages, are largely inaccessible to ribosomal synthesis and difficult to replicate by purely chemical means.

Synthetic Peptides

Chemical peptide synthesis, and solid-phase peptide synthesis, SPPS, in particular, liberates peptide chemistry from the constraints of both the ribosome and biosynthetic enzyme machinery.^[10] Any amino acid that can be protected and coupled can in principle be incorporated into a synthetic peptide, including the full range of D-amino acids, N-methylated residues, beta-amino acids, and entirely non-natural side chains. Chain lengths from dipeptides to sequences exceeding 100 residues are accessible, though longer sequences require convergent strategies such as native chemical ligation.

The freedom of chemical synthesis is the defining feature of synthetic peptide science. It enables systematic structure-activity relationship studies in which individual residues are replaced, deleted, or modified in a controlled way. It enables the incorporation of probes, labels, and functional handles at defined positions. It enables access to sequences and architectures that have no natural precedent. The methods underlying this freedom are the subject of Part II of this knowledge base.

Synthetic peptides are produced at scales ranging from nanomoles, for research applications, to metric tons, for approved therapeutic peptides such as semaglutide. The industrial synthesis of therapeutic peptides is a mature discipline with its own engineering challenges, distinct from those of laboratory-scale research synthesis.

Semi-Synthetic Peptides

Semi-synthetic peptides combine biological and chemical elements, typically by chemically modifying a peptide or protein derived from a biological source. The modification may introduce a synthetic handle, a non-natural amino acid, a lipid chain, a PEG polymer, or any other chemical feature that alters the properties of the parent molecule.

Insulin provides the clearest historical example. Early therapeutic insulin was extracted from bovine or porcine pancreatic tissue and modified chemically to improve its properties. Modern insulin analogues such as insulin glargine and insulin detemir are produced by recombinant expression followed by chemical modification, semi-synthetic by any reasonable definition. The synthesis of erythropoietin analogues bearing defined glycan structures, and the production of antibody-drug conjugates carrying cytotoxic peptide payloads, represent more recent examples of semi-synthetic strategies at the frontier of the field.

The Boundaries Are Increasingly Blurred

The categories outlined above, ribosomal, RiPP, non-ribosomal, synthetic, and semi-synthetic, are useful organizing frameworks rather than mutually exclusive definitions. Genetic code expansion allows the ribosome itself to incorporate non-canonical amino acids, producing ribosomally synthesized peptides with properties previously accessible only through chemical synthesis. Chemoenzymatic synthesis combines NRPS enzymes with chemical steps to access molecules inaccessible by either route alone. Native chemical ligation and expressed protein ligation allow synthetic and recombinant fragments to be joined into single molecules. The field is defined not by these categories but by the underlying chemistry of the peptide bond and the sequence-defined logic of peptide structure, which unifies all of these approaches.

Why This Matters for the Reader

Understanding the origin of a peptide under study is not merely historical context. It determines what structural features are present, what analytical methods are appropriate, what modifications are possible, and what synthetic routes are accessible. A natural product chemist and a medicinal chemist may study the same peptide scaffold and use entirely different vocabularies, methods, and conceptual frameworks. The knowledge base that follows covers all of these perspectives, because the field itself does not recognize the boundaries between them.